Free tool
FAERS Monitor: Elcys
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210660 or its brand name (Elcys, Cysteine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
25
Serious
24
96% of reports
Hospitalization
13
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hallucination6
- pneumonia4
- erythema multiforme3
- malaise3
- food craving2
- intentional product use issue2
- thirst2
- accidental exposure1
- altered state of consciousness1
- apnoea1
- atrial fibrillation1
- body temperature decreased1
- bronchial secretion retention1
- candida pneumonia1
- carnitine deficiency1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2012 | 7 |
| 2013 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2020 | 1 |
| 2021 | 3 |
| 2023 | 2 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,134 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| carnitine deficiency | 1 | 4953.9 | 721.7 | 1,230 |
| candida pneumonia | 1 | 2615.4 | 382.1 | 651 |
| bronchial secretion retention | 1 | 661.6 | 96.9 | 164 |
| food craving | 2 | 319.9 | 84.6 | 357 |
| erythema multiformeSignal | 3 | 270.7 | 93.6 | 559 |
| accidental exposure | 1 | 202.1 | 29.6 | 50 |
| apnoea | 1 | 108.1 | 15.8 | 26 |
| thirst | 2 | 94.2 | 24.9 | 103 |
| body temperature decreased | 1 | 85.5 | 12.5 | 20 |
| hallucinationSignal | 6 | 67.0 | 33.3 | 328 |
| altered state of consciousness | 1 | 38.8 | 5.7 | 9 |
| intentional product use issue | 2 | 19.2 | 5.1 | 19 |
| pneumoniaSignal | 4 | 10.4 | 4.2 | 26 |
| atrial fibrillation | 1 | 8.6 | 1.3 | 1 |
| malaiseSignal | 3 | 5.8 | 2.0 | 8 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.